Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer
Jamie M. Sperger(University of Wisconsin–Madison), Joshua M. Lang(University of Wisconsin–Madison), Michael J. Morris(Dana-Farber Cancer Institute), Xinyi E. Chen(University of British Columbia), Felix Y. Feng(University of Michigan), Mary‐Ellen Taplin(University of Massachusetts Chan Medical School), Hamid Emamekhoo(University of Wisconsin Carbone Cancer Center), Andrew J. Armstrong(Duke University), Lucia Kwak(Harvard University), Xiao X. Wei(Dana-Farber Cancer Institute), Glenn J. Bubley(Sidney Kimmel Comprehensive Cancer Center), Toni K. Choueiri(Harvard University), Susan Halabi(Duke Medical Center), Alexander W. Wyatt(University of British Columbia), Rana R. McKay(University of California San Diego), Scott M. Dehm(University of Minnesota), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Shuang G. Zhao(University of Wisconsin Carbone Cancer Center), Serena K. Wolfe(University of Wisconsin–Madison), Rebecca Silver(Forma Therapeutics (United States)), Cole S. Gilsdorf(University of Wisconsin–Madison), Charlotte N. Stahlfeld(University of Wisconsin–Madison), Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center), Zhenwei Zhang(Shenyang Pharmaceutical University), Anupama Singh(University of Wisconsin–Madison)
Cited by 62
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k